Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Insulet Co. (NASDAQ:PODD – Get Rating) have been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $330.00.

PODD has been the subject of a number of research analyst reports. Wolfe Research began coverage on shares of Insulet in a research report on Thursday, January 26th. They set a “peer perform” rating for the company. Piper Sandler upped their price target on Insulet from $340.00 to $360.00 in a report on Friday, May 5th. Raymond James boosted their target price on Insulet from $320.00 to $334.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. UBS Group increased their price target on Insulet from $328.00 to $360.00 in a research report on Friday, May 5th. Finally, Morgan Stanley boosted their price objective on Insulet from $320.00 to $325.00 and gave the stock an “equal weight” rating in a report on Friday, February 24th.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $296.43 on Wednesday. Insulet has a 12-month low of $192.33 and a 12-month high of $335.91. The company has a market cap of $20.66 billion, a PE ratio of 257.29, a P/E/G ratio of 6.41 and a beta of 0.80. The stock has a 50 day simple moving average of $316.73 and a 200-day simple moving average of $302.49. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 2.72.

Insulet (NASDAQ:PODD – Get Rating) last posted its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.14. The business had revenue of $358.10 million during the quarter, compared to the consensus estimate of $330.21 million. Insulet had a net margin of 0.04% and a return on equity of 17.29%. The company’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.40 earnings per share. On average, equities research analysts forecast that Insulet will post 1.34 EPS for the current year.

Insider Activity

In related news, insider Charles Alpuche sold 23,401 shares of the business’s stock in a transaction on Monday, March 13th. The stock was sold at an average price of $305.15, for a total value of $7,140,815.15. Following the sale, the insider now owns 45,584 shares of the company’s stock, valued at approximately $13,909,957.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Charles Alpuche sold 23,401 shares of the company’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $305.15, for a total value of $7,140,815.15. Following the sale, the insider now owns 45,584 shares of the company’s stock, valued at approximately $13,909,957.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Wayde D. Mcmillan sold 1,255 shares of Insulet stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $318.31, for a total transaction of $399,479.05. Following the transaction, the chief financial officer now directly owns 22,865 shares of the company’s stock, valued at $7,278,158.15. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,656 shares of company stock worth $9,819,174. Company insiders own 0.80% of the company’s stock.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently bought and sold shares of the business. Toroso Investments LLC grew its holdings in shares of Insulet by 13.6% during the first quarter. Toroso Investments LLC now owns 3,077 shares of the medical instruments supplier’s stock worth $981,000 after purchasing an additional 368 shares during the last quarter. Centaurus Financial Inc. acquired a new position in shares of Insulet during the first quarter worth approximately $107,000. Rockefeller Capital Management L.P. grew its stake in shares of Insulet by 809.0% during the first quarter. Rockefeller Capital Management L.P. now owns 110,819 shares of the medical instruments supplier’s stock valued at $35,345,000 after purchasing an additional 98,628 shares during the last quarter. Chevy Chase Trust Holdings LLC acquired a new stake in shares of Insulet in the first quarter valued at approximately $12,873,000. Finally, KB Financial Partners LLC bought a new position in Insulet in the 1st quarter valued at $70,000.

Insulet Company Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.